# Who does ALTEOGEN pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/alteogen · Facet: suppliers · Updated: 2026-07-12T04:03:43.631+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: ALTEOGEN discloses no named confirmed suppliers/cost counterparties; 3 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 3 cost edges, backed by 1 dated sources, 1 of them primary filings (as of 2026-07-12).

### 해외 CMO (ALT-B4 위탁생산) (mid)
- metric: Amount ₩58B · 2025 외주가공비(국내+수입) · DART annual report
- note: With no mass-production plant yet, Alteogen outsources preclinical/clinical material and commercial ALT-B4 to domestic and overseas CMOs. FY2025 outsourced processing cost was about 58.0bn won (including US$23.6M imported). GMP production and a European CMO contract are in place.
- [confirms] FSS DART (KO, filing, published 2026-03-23) https://opendart.fss.or.kr/api/document.xml?rcept_no=20260323001596: "Alteogen has no mass-production plant yet; preclinical/clinical material is made by domestic and overseas CMOs. FY2025 outsourced processing: 24.08bn (domestic) + 33.90bn (import) ≈ 58.0bn won (US$23.6M imported)."

### CRO·연구개발 외주용역 (mid)
- metric: Amount ₩33.2B · 2025 연구개발 외주용역비 · DART annual report
- note: Preclinical, clinical and some experimental work is outsourced to external CROs for pipeline development. FY2025 R&D outsourcing cost was about 33.2bn won, within total R&D spend of about 57.3bn won (28.2% of revenue).
- [confirms] FSS DART (KO, filing, published 2026-03-23) https://opendart.fss.or.kr/api/document.xml?rcept_no=20260323001596: "R&D expense comprises personnel, reagents/materials and outsourcing per pipeline. FY2025 R&D outsourcing was 33.2bn won within total R&D of 57.3bn won (28.24% of revenue)."

### 원부자재 공급사 (배지·시약) (mid)
- metric: Amount ₩11.1B · 2025 원재료 매입 소계 · DART annual report
- note: Purchases of raw materials for commercial production and reagents/lab supplies for R&D. Many items are made by overseas manufacturers and imported through domestic agents, exposing costs to FX. FY2025 raw-material purchases totaled about 11.1bn won.
- [confirms] FSS DART (KO, filing, published 2026-03-23) https://opendart.fss.or.kr/api/document.xml?rcept_no=20260323001596: "Raw materials cover inputs for commercial production and R&D reagents/tools; many are imported via domestic agents and exposed to FX. FY2025 raw-material purchases totaled 11.14bn won."

Reverse side: https://valuechain.wiki/alteogen/customers.md · Ripple: https://valuechain.wiki/alteogen/ripple.md

---
Full node: https://valuechain.wiki/alteogen.md · JSON: https://valuechain.wiki/alteogen.json